Tags

Type your tag names separated by a space and hit enter

Conivaptan: promise of treatment in heart failure.
Expert Opin Pharmacother. 2009 Sep; 10(13):2161-9.EO

Abstract

Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients. The renin-angiotensin-aldosterone system is activated in heart failure (HF) causing clinical worsening. Arginine vasopressin levels are also elevated in HF. Conivaptan is an effective and FDA approved for the treatment of euvolemic and hypervolemic hyponatremia and may offer an extra treatment option in HF by targeting V(1a) and V(2) receptors. In this article we review the physiology, preclinical studies as well as the human clinical studies on the use of conivaptan and its potential and promise in the treatment of HF.

Links

Publisher Full Text

Authors+Show Affiliations

Hoque MZ
Albert Einstein Medical Center, Cardiology, 5501 Old York Road, Philadelphia, PA 19141, USA.
Arumugham P
No affiliation info available
Huda N
No affiliation info available
Verma N
No affiliation info available
Afiniwala M
No affiliation info available
Karia DH
No affiliation info available

MeSH

Antidiuretic Hormone Receptor AntagonistsBenzazepinesClinical Trials as TopicHeart FailureHumansHyponatremiaReceptors, Vasopressin

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19663609

Citation

Hoque, Mohammad Z., et al. "Conivaptan: Promise of Treatment in Heart Failure." Expert Opinion On Pharmacotherapy, vol. 10, no. 13, 2009, pp. 2161-9.
Hoque MZ, Arumugham P, Huda N, et al. Conivaptan: promise of treatment in heart failure. Expert Opin Pharmacother. 2009;10(13):2161-9.
Hoque, M. Z., Arumugham, P., Huda, N., Verma, N., Afiniwala, M., & Karia, D. H. (2009). Conivaptan: promise of treatment in heart failure. Expert Opinion On Pharmacotherapy, 10(13), 2161-9. https://doi.org/10.1517/14656560903173237
Hoque MZ, et al. Conivaptan: Promise of Treatment in Heart Failure. Expert Opin Pharmacother. 2009;10(13):2161-9. PubMed PMID: 19663609.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Conivaptan: promise of treatment in heart failure. AU - Hoque,Mohammad Z, AU - Arumugham,Pradeep, AU - Huda,Nazmul, AU - Verma,Nitin, AU - Afiniwala,Mitul, AU - Karia,Darshak H, PY - 2009/8/12/entrez PY - 2009/8/12/pubmed PY - 2009/10/16/medline SP - 2161 EP - 9 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 10 IS - 13 N2 - Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients. The renin-angiotensin-aldosterone system is activated in heart failure (HF) causing clinical worsening. Arginine vasopressin levels are also elevated in HF. Conivaptan is an effective and FDA approved for the treatment of euvolemic and hypervolemic hyponatremia and may offer an extra treatment option in HF by targeting V(1a) and V(2) receptors. In this article we review the physiology, preclinical studies as well as the human clinical studies on the use of conivaptan and its potential and promise in the treatment of HF. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/19663609/Conivaptan:_promise_of_treatment_in_heart_failure_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656560903173237 DB - PRIME DP - Unbound Medicine ER -